Research & Development
Universal CAR-T Platform

Gene-Editing Free:
A Safer Foundation

REVO-U is designed to create a next-generation universal CAR-T product without plasmids, nucleases, or DNA double-strand breaks.

No plasmids. No nucleases. No DNA damage. Protein-directed TCR surface elimination supports a safer allogeneic CAR-T foundation.
CAR molecule TCR-CD3 complex CD3 degradation IMPDH Armor
Diagram showing a gene-editing free REVO-U universal CAR-T engineering approach with protein-directed TCR surface elimination and engineered CAR-T features. IMPDH Revo-U Engineering TCR-CD3 complex disassembly CD3 elements degradation No plasmids. No nucleases. No DNA damage. Protein-directed TCR elimination for a safer allogeneic CAR-T foundation. CAR molecule TCR-CD3 complex CD3 elements CD3 elements IMPDH Armor
Why It Matters

Why a Next-Generation Universal CAR-T Platform Is Needed

Conventional universal CAR-T strategies often require multiple gene edits plus CAR transduction. REVO-U is designed to simplify manufacturing while reducing phenotype heterogeneity.

Typical genes edited: TCR HLA-A HLA-B / B2M CD52 CIITA + CAR transduction by LVV
Challenges in Current U-CAR
1

Safety Concerns

Off-target risk and chromosome translocation concerns from gene editing.

2

Complex Supply Chain and High COGS

Expensive electroporation devices and GMP-grade materials such as gRNAs, dsDNA, Cas9 proteins and LVV.

3

High Heterogeneity

Variable gene-editing efficiency can lead to heterogeneous phenotypes and residual GvHD risk from CAR+TCR+ cells.

4

Poor Scalability

Lengthy multi-step processes can contribute to poor cell function and limited yields.

CAR+TCR− CAR+TCR+ GvHD risk CAR−TCR− CAR−TCR+ + − + + − − − + TCR expression CAR expression
The combination of multiple gene edits and CAR transduction can create many possible phenotypic combinations.
Next-gen REVO-U CAR Technology
1

More Natural Biology

Non-gene-editing approach to handle GvHD or HvGR; no DNA double-strand breaks and no chromosome translocation risk.

2

Simple CMC & Low COGS

Manufacturing process similar to autologous CAR-T, requiring only LVV; no plasmids needed throughout the process.

3

High Purity

Near-100% CAR+TCR− phenotype in the final product.

4

Great Scalability

Up to 3,000 doses per batch using one clean-room unit in short time; manufacturing capacity expandable with limited investment.

The next-generation platform is scalable to industrial-scale manufacturing, comparable to biologic drugs.
Manufacturing Advantage

Industrial-Scale Manufacturing

REVO-U is designed for large batch output with a streamlined workflow, moving from complex gene-edited production toward biologics-like scalability.

Gene-edited Universal CAR-T

25–100 doses / batch

High cost

REVO-U Manufacturing
>3,000 doses / batch

Scalable like biologics

Final Product Profile

Near-100% CAR+TCR− Phenotypic Purity

Protein-directed TCR surface elimination creates a phenotypically uniform, safer cell population.

Residual GvHD risk
Near-100% CAR+TCR−
Protein-directed TCR surface elimination creates a phenotypically uniform, safer cell population.
Functional Enhancement

Enhanced Cell Fitness & Persistence

REVO-U combines IMPDH-mediated MPA resistance with a proprietary co-stimulatory armor module to support long-term functional persistence.

IMPDH
↓
MPA resistance
Survival
Anti-Exhaustion
Long-Term
Persistence
Engineered Armor Receptor
A proprietary co-stimulatory armor module supports survival, resistance to exhaustion, and long-term persistence.
  • North Area, Building E, Floors 3-4, Qianhai Shenzhen-Hong Kong Youth Innovation Hub, Nanshan District, Shenzhen, Guangdong Province, China
  • 0755-86971801

微信公众号

Copyright © 2024 Wondercel Therapeutics Powered by vancheer